PaxMedica

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PaxMedica and buy or sell other stocks, ETFs, and their options commission-free!

About PXMD

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. 

CEO
Howard J. Weisman
CEOHoward J. Weisman
Employees
5
Employees5
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
2018
Founded2018
Employees
5
Employees5

PXMD Key Statistics

Market cap
12.04K
Market cap12.04K
Price-Earnings ratio
-0.09
Price-Earnings ratio-0.09
Dividend yield
Dividend yield
Average volume
11.11M
Average volume11.11M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$4.07
52 Week high$4.07
52 Week low
$0.1471
52 Week low$0.1471

Stock Snapshot

The current PaxMedica(PXMD) stock price is $0.00, with a market capitalization of 12.04K. The stock trades at a price-to-earnings (P/E) ratio of -0.09.

On 2026-03-11, PaxMedica(PXMD) stock opened at —, reached a high of —, and a low of —.

The PaxMedica(PXMD)'s current trading volume is 0, compared to an average daily volume of 11.11M.

In the last year, PaxMedica(PXMD) shares hit a 52-week high of $4.07 and a 52-week low of $0.15.

In the last year, PaxMedica(PXMD) shares hit a 52-week high of $4.07 and a 52-week low of $0.15.

People also own

Based on the portfolios of people who own PXMD. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.